MXPA02008462A - Modulacion de la actividad de receptor de superficie celular endotelial en la regulacion de angiogenesis. - Google Patents

Modulacion de la actividad de receptor de superficie celular endotelial en la regulacion de angiogenesis.

Info

Publication number
MXPA02008462A
MXPA02008462A MXPA02008462A MXPA02008462A MXPA02008462A MX PA02008462 A MXPA02008462 A MX PA02008462A MX PA02008462 A MXPA02008462 A MX PA02008462A MX PA02008462 A MXPA02008462 A MX PA02008462A MX PA02008462 A MXPA02008462 A MX PA02008462A
Authority
MX
Mexico
Prior art keywords
angiogenesis
ecrtp
dep
modulation
regulation
Prior art date
Application number
MXPA02008462A
Other languages
English (en)
Spanish (es)
Inventor
Thomas O Daniel
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/516,728 external-priority patent/US7176289B1/en
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of MXPA02008462A publication Critical patent/MXPA02008462A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MXPA02008462A 2000-03-01 2001-02-27 Modulacion de la actividad de receptor de superficie celular endotelial en la regulacion de angiogenesis. MXPA02008462A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/516,728 US7176289B1 (en) 1998-09-11 2000-03-01 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
PCT/US2001/006178 WO2001064750A2 (en) 2000-03-01 2001-02-27 Modulation of the activity of the endothelial cel surface receptor ecrtp/dep-1 in the regulation of angiogenesis

Publications (1)

Publication Number Publication Date
MXPA02008462A true MXPA02008462A (es) 2004-05-14

Family

ID=24056849

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02008462A MXPA02008462A (es) 2000-03-01 2001-02-27 Modulacion de la actividad de receptor de superficie celular endotelial en la regulacion de angiogenesis.

Country Status (7)

Country Link
EP (1) EP1261644A2 (ja)
JP (1) JP2004507210A (ja)
AU (1) AU3989801A (ja)
CA (1) CA2401621A1 (ja)
IL (2) IL151370A0 (ja)
MX (1) MXPA02008462A (ja)
WO (1) WO2001064750A2 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2503736A1 (en) * 2002-11-26 2004-06-10 Cold Spring Harbor Laboratory Dep-1 receptor protein tyrosine phosphatase interacting proteins and related methods
CA2561861A1 (en) * 2004-04-23 2005-12-15 Amgen Inc. Antibodies to angiogenesis inhibiting domains of cd148
KR20070007884A (ko) * 2004-04-23 2007-01-16 암젠 인크 Ｃｄ148의 혈관신생 억제 도메인의 항체
EP4034561A2 (en) * 2019-09-27 2022-08-03 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
US11723926B2 (en) 2019-09-27 2023-08-15 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0708831T4 (da) * 1994-05-03 2008-04-14 Cold Spring Harbor Lab Celledensitetsforstærkede proteintyrosinphosphataser
US6248327B1 (en) * 1998-09-11 2001-06-19 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis

Also Published As

Publication number Publication date
JP2004507210A (ja) 2004-03-11
WO2001064750A3 (en) 2002-01-24
IL151370A (en) 2010-11-30
WO2001064750A2 (en) 2001-09-07
EP1261644A2 (en) 2002-12-04
CA2401621A1 (en) 2001-09-07
AU3989801A (en) 2001-09-12
IL151370A0 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
AU1914795A (en) Monoclonal antibodies specific to vegf receptors and uses thereof
IL143596A0 (en) Vascular endothelial cell growth factor antagonists and uses thereof
DE69833118D1 (de) Immunoassay zum bestimmen von bnp
AU6954398A (en) Antagonistic anti-avb3 integrin antibodies
HK1020990A1 (en) Antibodies to the ed-b domain of fibronectin, their construction and uses
IL200056A (en) Composition comprising an isolated agonistic antibody which specifically cross reacts with different apo - 2l receptors for use in inducing apoptosis in mammalian cancer cells
TR201900581T4 (tr) Opgl ye karşı antikorlar.
YU25302A (sh) Upotreba april receptora (vcma)
IL126314A0 (en) Monoclonal specific antibodies
AU9386398A (en) Cysteine rich receptors: trail
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
DK2042509T3 (da) Modulatorer af funktionen af fas-receptorer og andre proteiner
ATE229036T1 (de) Il-8 inhibitoren
ATE279443T1 (de) A3c6e2, ein monoklonaler antikörper spezifisch für den humanen stammzellfaktor (scf)-rezeptor
MXPA02008462A (es) Modulacion de la actividad de receptor de superficie celular endotelial en la regulacion de angiogenesis.
BR0011741A (pt) Compostos de organossilila tendo atividade de modulação do receptor de hormÈnio nuclear
DE69732762D1 (de) Indanderivate für antipsychotische mittel
HK1041273A1 (en) Compositions and method for generating monoclonal antibodies representative of a specific cell type
DE69427484T2 (de) Angiotensin ii rezeptor typ i spezifische monoklonale antikörper und hybridoma
ATE288485T1 (de) Monoklonaler antikörper 4g8b4b12 gegen humanes flt3/flk2
NO900871L (no) Mekanisk dempningssystem for flytende konstruksjon.
ATE215598T1 (de) Monoklonale antikörper, die flk-2-rezeptoren erkennen, und die isolierung primitiver hämatopoietischer stammzellpopulationen
DE3851221D1 (de) Nichttrennender festphasen-enzymtest.
ATE251643T1 (de) Antikörper 67d2 gegen cd164
PL348816A1 (en) A METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN-β RECEPTOR IMMUNOGLOBULIN CHIMERIC PROTEINS AND THEIR PURIFICATION